Fei Shen, Director, Global Compound Development Team Leader (CDTL) at Johnson & Johnson, shared a post on LinkedIn:
“Thrilled to share our recent publication of the Phase 3 AMPLITUDE trial results in Nature Medicine!
This landmark study demonstrates the clinical benefit of combining niraparib with abiraterone acetate plus prednisone (AAP) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) harboring homologous recombination repair (HRR) gene alterations.
At Johnson and Johnson, we remain deeply committed to advancing precision oncology and transforming outcomes for patients through innovative science and collaboration. A heartfelt thank you to all the investigators, patients, caregivers, and families who made the AMPLITUDE trial possible. Your contributions are helping shape the future of cancer care.”
Title: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Authors: Attard, Gerhardt; Agarwal, Neeraj; Graff, Julie N.; Sandhu, Shahneen; Efstathiou, Eleni; Özgüroğlu, Mustafa; Pereira de Santana Gomes, Andrea J.; Vianna, Karina; Luo, Hong; Gotto, Geoffrey T.; Cheng, Heather H.; Kim, Won; Varela, Carly R.; Schaeffer, Daneen; Kramer, Kassie; Li, Susan; Baron, Benoit; Shen, Fei; Mundle, Suneel D.; McCarthy, Sharon A.; Olmos, David; Chi, Kim N.; Rathkopf, Dana
Read the Full Article.
Eleni Efstathiou, MD PhD Genitourinary Oncology Section Chief at Houston Methodist, shared a post by Fei Shen, adding:
“In the past 10 years we have come a long way in developing treatment for hormone naive advanced prostate cancer. We were literally just using ADT before 2015.
This landmark trial is the first to exhibit benefit of a targeted triplet therapy for HRR deficient tumors in this disease stage. It makes the strongest case for upfront genomic sequencing.
And this is just the beginning.”